X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan, Hong Kong and Macau.
Lead Product(s): Zastaprazan
Therapeutic Area: Gastroenterology Product Name: JP 1366
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Onconic Therapeutics
Deal Size: $127.5 million Upfront Cash: $15.0 million
Deal Type: Acquisition March 14, 2023
Details:
Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the greater China territory.
Lead Product(s): LZM009
Therapeutic Area: Oncology Product Name: LZM009
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bright Peak Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 16, 2021
Details:
LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Asenapine TTS
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: LTS - Lohmann Therapie Systeme
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
